Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Awakn Life Sciences Corp (OP: AWKNF )

0.4447 -0.0753 (-14.48%)
Streaming Delayed Price Updated: 1:38 PM EDT, Jun 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 748
Open 0.4011
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.5200
Today's Range 0.4011 - 0.4447
52wk Range 0.3968 - 2.670
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Michael Pollan's 'How To Change Your Mind' Coming Soon To Netflix: Documentary Based On Psychedelics Best Seller
The freshest news traversing many of the major institutions, researchers' and activists’ accounts on Twitter is the recent release of a docu-series based on writer Michael Pollan’s 2018 book “How To... 
Via Benzinga
These 18 Clinical Trials Could Shape The Future Of The Psychedelics Industry
In the nascent industry of medical psychedelics, drug development is the name of the game. This subset of biotech, poised to become a $100 billion industry according to Canaccord Genuity, bases its... 
Via Benzinga

Performance

YTD
-78.57%
-78.57%
1 Month
-53.96%
-53.96%
3 Month
-65.26%
-65.26%
6 Month
-78.15%
-78.15%
1 Year
-69.73%
-69.73%

More News

Read More
Psyched: Medical Psychedelics In Davos, Canadian Sen Does Psychedelics, Ei.Ventures & Mycotopia To Merge Into $383M Company
Via Benzinga
Awakn Life Sciences Reports Completing World's First Ketamine Study For A Range Of Behavioral Addictions
Via Benzinga
Awakn's Study On Psychedelics For Treating Addiction Shows Promise, Will Undertake Broader Research
Via Benzinga
Wake-Up Call: This Biotech Company Is Using Psychedelics To Treat Addiction
Via Benzinga
Core One Labs Begins Trading On OTCQB
Via Benzinga
Psyched: Atai, MindMed, Enveric and Mydecine Release 2021 Earnings, Bienstar Expands To Brazil & More!
Via Benzinga
Stifel Initiates Coverage On Awakn Life Sciences With A Speculative Buy, $8 Target Price Target
Via Benzinga
This Biotech Company Is Landing Ketamine-Assisted Therapy In England's Capital
Via Benzinga
Awakn Life Sciences Seeks To Treat Addictions: Gambling, Binge Eating And Compulsive Sexual Behavior
Via Benzinga
This Ketamine-Assisted Therapy Company Is Developing New Ways To Treat Alcohol Addiction
Via Benzinga
Psychedelic And Cannabis Drug Stocks Continue Advance
Via Talk Markets
Mindset Pharma, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
Mind Medicine, Allied Among Top Psychedelic Movers Of Today
Via Benzinga
Has A Sugar Daddy Emerged In The Psychedelic Drug Industry?
Via Talk Markets
The Psychedelic & Marijuana Drug Stocks Index Dropped -30% In January
Via Talk Markets
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From January 24, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From January 21, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From January 20, 2022
Via Benzinga
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From January 18, 2022
Via Benzinga
Psyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS
Via Benzinga
Ketamine Therapy Shows Potential In Treatment Of Alcohol Use Disorder, New Study Finds
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.